Company intelligence / Profile preview

CrannMed

Ownership: Private
Development stage: Other

Overview

CrannMed has developed Embosure Microspheres, resorbable embolic particles designed for targeted genicular artery embolization as a minimally invasive treatment for knee osteoarthritis. The company has received Breakthrough Device Designation from the FDA and continues to work toward market approval. Clinical results are not yet published or detailed publicly.

Therapeutic areas: Rheumatology
Modalities: Device (Resorbable embolic particles/microspheres)Catheter-based delivery system
Industry: Therapeutic Medical Devices

Partnerships

Meditrial Inc. (regulatory and clinical development partner)

Beyond the preview

Go deeper on CrannMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CrannMed.

Explore the full profile